Bedrosian Camille L
Director | Chief Medical Officer | EVP And Chief Medical Officer
4 companies
Insider Signal Score
64
GoodTrades Analyzed
13
12M Win Rate
63.6%
Avg 3M Return
+6.4%
Avg 12M Return
-1.1%
Bedrosian Camille L is a Chief Medical Officer at AMLX with holdings across 4 companies. Recent SEC Form 4 filings include 0 buys and 6 sells.
Estimated insider holdings value: $7.7M based on current market prices.
Holdings by Company
AMLXDec 1, 2025
Current Shares175.8K
Value$3.84M
Net Activity-47,907
Bought: 0Sold: 47.9K
RAREMar 1, 2023
Current Shares50.6K
Value$1.26M
Net Activity-51,130
Bought: 0Sold: 51.1K
CRNXJun 18, 2026
Current Shares22.2K
Value$1.87M
Net Activity0
Bought: 0Sold: 0
RYTMJun 18, 2025
Current Shares7.0K
Value$775.0K
Net Activity0
Bought: 0Sold: 0
Transaction History
Showing 6 filings (page 2)
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2021 | RARE Ultragenyx Pharmaceutical Inc. | EVP And Chief Medical Officer | Sell | 364 | $113.67 | $41,375.88 | -0.9% | -26.2% | -50.3% | |
| Apr 15, 2021 | RARE Ultragenyx Pharmaceutical Inc. | EVP And Chief Medical Officer | Sale+OE | 5,000 | $109.09 | $545,450.00 | -11.3% | -22.7% | -22.1% | |
| Mar 1, 2021 | RARE Ultragenyx Pharmaceutical Inc. | EVP And Chief Medical Officer | Sell | 4,543 | $138.18 | $627,751.74 | -10.4% | - | - | |
| Jan 30, 2021 | RARE Ultragenyx Pharmaceutical Inc. | EVP And Chief Medical Officer | Sell | 2,243 | $140.36 | $314,827.48 | -6.3% | - | - | |
| Jan 15, 2021 | RARE Ultragenyx Pharmaceutical Inc. | EVP And Chief Medical Officer | Sale+OE | 25,000 | $139.18 | $3,479,500.00 | -41.1% | - | - | |
| Oct 14, 2020 | RARE Ultragenyx Pharmaceutical Inc. | EVP And Chief Medical Officer | Sell | 262 | $88.00 | $23,056.00 | -0.7% | - | - |
← PrevPage 2